Saxenda FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved December 23, 2014)
Brand name: Saxenda
Generic name: liraglutide
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Weight Loss (Obesity/Overweight)
Saxenda (liraglutide) is a once-daily glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.
Development timeline for Saxenda
| Date | Article |
|---|---|
| Dec 4, 2020 | Approval FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17 |
| Dec 23, 2014 | Approval FDA Approves Saxenda (liraglutide [rDNA origin] injection) for Obesity |
| Sep 11, 2014 | FDA Advisory Committee Votes 14-1 in Favor of Saxenda (liraglutide) for Obesity |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
